Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality

Gut

Volumn 40, Issue 4, 1997, Pages 544-549

  Homann, C ^a,g   Varming, K ^b   Hogasen K ^c   Mollnes, T E ^d,e   Graudal, N ^a   Thomsen, A C ^a   Garred, P ^f  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF OSLO   (Norway)

^d NORDLAND HOSPITAL   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

^f Rigshospitalet   (Denmark)

^g GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cirrhosis; Complement; Infection; Prognosis

Indexed keywords

COMPLEMENT COMPONENT C3;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BACTERIAL INFECTION; COMPLEMENT DEFICIENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031008871     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.4.544     Document Type: Article

References (29)

1. Wyke RJ. Problems of bacterial infection in patients with liver disease. Gut 1987; 28: 623-41.
2. Frank MM. Complement in the pathophysiology of human disease. N Engl J Med 1987; 316: 525-30.
3. Horwitz M. Phagocytosis of microorganisms. Rev Infect Dis 1982; 4: 104-23.
4. Agnello V. Complement deficiency states. Medicine 1978; 57: 1-23.
5. Finlayson NDC, Krohn K, Fauconnet MH, Anderson KE. Significance of serum complement levels in chronic liver disease. Gastroenterology 1972; 63: 653-9.
6. Kourilsky O, Leroy C, Peltier AP. Complement and liver cell function in 53 patients with liver disease. Am J Med 1973; 55: 783-90.
7. Potter BJ, Trueman AM, Jones EA. Serum complement in chronic liver disease. Gut 1973; 14: 451-6.
8. Potter BJ, Elias E, Fayers PM, Jones EA. Profiles of serum complement in patients with hepatobiliary diseases. Digestion 1978; 18: 371-83.
9. Ellison RT III, Horsburgh R Jr, Curd J. Complement levels in patients with hepatic dysfunction. Dig Dis Sci 1990; 35: 231-5.
10. Fox RA, Dudley FJ, Sherlock S. The serum concentration of the third component of complement β1C/β1A in liver disease. Gut 1971; 12: 574-8.
11. Munoz LE, De Villiers D, Markham D, Whaley K, Thomas HC. Complement activation in chronic liver disease. Clin Exp Immunol 1982; 47: 548-54.
12. Gluud C, Jans H. Circulating immune complexes and complement concentrations in patients with alcoholic liver disease. J Clin Pathol 1982; 35: 380-4.
13. Such J, Guarner C, Enriquez J, Rodriguez JL, Seres I, Vilardell F. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988; 6: 80-4.
14. Runyon BA. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 1988; 8: 632-5.
15. Mal F, Pham Huu T, Bendahou M, Trinchet JC, Gardier M, Hakim J, et al. Chemoattractant and opsonic activity in ascitic fluid. A study in 47 patients with cirrhosis or malignant peritonitis. J Hepatol 1991; 12: 45-9.
16. Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104: 1133-8.
17. Homann C, Garred P, Hasselqvist P, Graudal N, Thiel S, Thomsen ÅC. Mannan-binding protein and complement dependent opsonization in alcoholic cirrhosis. Liver 1995; 15: 39-44.
18. Homann C, Garred P, Graudal N, Hasselqvist P, Christiansen M, Fagerhol MK, et al. Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology 1995; 21: 979-85.
19. Mollnes TE, Tschopp J. A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9. J Immunol Methods 1987; 100: 215-21.
20. Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329-35.
21. Mollness TE, Redl H, Høgåsen K, Bengtsson A, Garred P, Speilberg L, et al. Complement activation in septic baboons detected by neoepitope specific assays for C3b/ iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993; 91: 295-300.
22. Polhill RB Jr, Pruitt KM, Johnston RB Jr. Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses. J Immunol 1978; 121: 363-70.
23. Broackle RJ, Pruitt KM. A convenient method for the study of anticomplementary substances in biological fluids. In: Peeters H, eds. Protides of the biological fluids. Oxford: Pergamon Press, 1974; 21: 613-7.
24. Ferrante A, Thong YH. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leucocytes from human blood using a modification of the Hypaque/Ficoll technique. J Immunol Methods 1978; 24: 389-93.
25. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology 1987; 7: 1346-58.
26. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels by chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988; 8: 232-6.
27. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987; 4: 8-14.
28. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-9.
29. Wessels MR, Butko P, Ma MH, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 and C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 1995; 92: 11490-4.